A Gaithersburg biotech that’s developing regenerative therapies for wound care has continued to broaden its scope by acquiring a North Carolina company focused on stem cell treatments for stroke and other conditions.
In an all-stock transaction, publicly traded Cytomedix agreed last week to pay $16 million — and up to $40 million, if certain milestones are achieved — for privately held Aldagen of Durham, N.C. As part of the deal, Aldagen investors bought $5 million of Cytomedix common stock in a private placement.
To read the full, original article click on this link: Gazette.Net: Cytomedix expands reach with North Carolina acquisition
